# Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

> **NCT01056029** · PHASE1 · COMPLETED · sponsor: **GenSpera, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** G-202

## Key facts

- **NCT ID:** NCT01056029
- **Lead sponsor:** GenSpera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-12
- **Final completion:** 2013-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2015-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01056029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01056029, "Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01056029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*